Xcellon Biologics is a contract development and manufacturing organisation (CDMO) based in North Bethesda, Maryland. The company focuses on the development and manufacturing of complex biologics, with a particular emphasis on antibody–drug conjugates (ADCs), bispecific antibodies, and T-cell engagers. Xcellon Biologics offers a comprehensive range of services, from early-stage research and development to clinical and commercial manufacturing, aiming to accelerate the delivery of life-saving therapies.

Key Products and Services

ADC & Bioconjugate Lead Selection: Utilising advanced techniques to identify and select optimal lead candidates for ADC development.

ADC & Bioconjugate Development: Providing end-to-end services for the development of ADCs and bioconjugates, including conjugation, purification, and characterisation.

Bioprocess Development: Developing scalable and robust manufacturing processes for biologics.

Analytical & Formulation Development: Offering analytical testing and formulation development to ensure the stability and efficacy of biologic products.

Data Analytics & Machine Learning: Implementing data-driven approaches to optimise processes and enhance decision-making.

GMP Manufacturing: Providing Good Manufacturing Practice (GMP) compliant manufacturing services, with capabilities expected to be online in 2026.

Strategically located near key U.S. federal healthcare agencies such as the FDA, NIH, and USP, Xcellon Biologics is positioned to play a significant role in advancing the next generation of biologic therapies. With a commitment to innovation, quality, and efficiency, the company collaborates with biopharmaceutical leaders to address the most complex challenges in biologics development and manufacturing.